- Report
- May 2023
- 169 Pages
Global
From €2266EUR$2,350USD£1,938GBP
- Drug Pipelines
- January 2024
- 60 Pages
Global
From €1446EUR$1,500USD£1,237GBP
- Report
- February 2021
- 360 Pages
United States
From €2314EUR$2,400USD£1,979GBP
- Report
- February 2019
- 105 Pages
Global
From €1244EUR$1,290USD£1,064GBP
- Report
- July 2019
Global
From €964EUR$1,000USD£825GBP
- Drug Pipelines
- June 2019
- 579 Pages
Global
€21210EUR$22,000USD£18,140GBP
- Report
- June 2019
- 16 Pages
Global
€9641EUR$10,000USD£8,245GBP
- Report
- June 2019
- 16 Pages
Global
€9641EUR$10,000USD£8,245GBP
- Report
- February 2021
- 254 Pages
Global
From €10600EUR$10,995USD£9,066GBP
- Report
- April 2021
- 64 Pages
Global
€21210EUR$22,000USD£18,140GBP
- Report
- June 2019
- 15 Pages
Japan
€9641EUR$10,000USD£8,245GBP
- Report
- June 2019
- 16 Pages
Global
€9641EUR$10,000USD£8,245GBP
- Report
- June 2019
- 14 Pages
Global
€9641EUR$10,000USD£8,245GBP
- Report
- June 2019
- 16 Pages
Global
€9641EUR$10,000USD£8,245GBP
- Report
- November 2023
- 35 Pages
Global
From €5611EUR$5,820USD£4,799GBP
Biktarvy is a combination drug used to treat HIV/AIDS. It is a single-tablet regimen that combines three antiretroviral drugs: bictegravir, emtricitabine, and tenofovir alafenamide. Biktarvy is used to treat HIV-1 infection in adults and adolescents aged 12 years and older. It is also used to reduce the risk of HIV-1 infection in adults and adolescents who are at high risk of HIV-1 infection. Biktarvy works by blocking the action of the virus in the body, preventing it from multiplying and spreading.
The Biktarvy market is a rapidly growing segment of the HIV/AIDS drugs market. It is a highly competitive market, with several companies offering their own versions of the drug. Companies in the Biktarvy market include Gilead Sciences, Mylan, and ViiV Healthcare. Show Less Read more
